Education
About Us
Working with TipRanks
Follow Us
Beyond Air Inc (XAIR)
NASDAQ:XAIR
Top Page
Beyond Air
(NASDAQ:XAIR)
Rating:43Neutral
Price Target:
$0.00
▼(-100.00%Downside)
Positive Factors
Financial Performance
3Q25 LungFit PH revenue of $1.1M was above our estimate of $0.88M.
Market Expansion
The company secured new distribution partnerships in Europe and the Middle East, reaching a total of more than 25 countries covered.
Product Innovation
Beyond Air's systems deliver unlimited and on-demand nitric oxide from ambient air via ionization with its patented Plasma Pulse Technology, offering a simpler solution compared to competitor systems that use cumbersome and risky compressed gas cylinders.
Negative Factors
Cash Management
Cash burn is anticipated to continue trending lower, but not to the same extent as F3Q due to planned submission activities.
Revenue Challenges
Beyond Air faced setbacks and challenges in its initial commercial efforts, which limited its ability to achieve substantial revenue due to delays and disruptions during the COVID-19 pandemic and a failed agreement with a partner.
Beyond Air (XAIR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.30M
Dividend YieldN/A
Average Volume (3M)4.07M
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth219.67%
EPS Growth56.69%
CountryUS
Employees107
SectorHealthcare
Sector Strength40
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.09
Shares Outstanding92,794,780
10 Day Avg. Volume1,967,076
30 Day Avg. Volume4,068,564
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.80
Price to Sales (P/S)0.00
P/FCF Ratio-0.31
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit-12.53
Enterprise Value/Ebitda-0.11
Forecast
1Y Price Target
$1.33Price Target Upside533.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Beyond Air Business Overview & Revenue Model
Company DescriptionBeyond Air, Inc. (XAIR) is a medical device and biopharmaceutical company focused on developing and commercializing innovative products for patients with respiratory conditions. The company's core technology is centered around the LungFit™ platform, which is designed to deliver nitric oxide for therapeutic use in various respiratory diseases. Beyond Air operates within the healthcare sector, specifically targeting the medical devices and respiratory therapy markets.
How the Company Makes MoneyBeyond Air generates revenue primarily through the commercialization of its LungFit™ platform, which delivers nitric oxide for treating respiratory conditions such as bronchiolitis and chronic obstructive pulmonary disease (COPD). The company aims to monetize its technology by obtaining regulatory approvals, launching its devices in key markets, and establishing partnerships with healthcare providers and distributors. Beyond Air's revenue model focuses on selling or leasing its devices to hospitals and clinics, as well as potentially earning royalties or licensing fees from strategic partnerships. Additionally, the company invests in research and development to expand the therapeutic applications of its platform and enhance its market potential.
Beyond Air Earnings Call Summary
Earnings Call Date:Jun 17, 2025
(Q4-2025)
| % Change Since: -25.00%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call presents a generally positive outlook driven by significant revenue growth, strong future guidance, and successful international expansion. However, financial challenges such as net loss and cost exceedances are areas of concern.Q4-2025 Updates
Positive Updates
Record-Breaking Revenue Growth
For the fiscal year ended March 31, 2025, Beyond Air reported a 220% increase in revenue to $3.7 million compared with $1.2 million for the same period last year.
Strong Revenue Guidance
The company provided revenue guidance of $12 million to $16 million for the full fiscal year ending March 31, 2026, indicating sustained high growth.
Expansion into International Markets
Beyond Air has expanded its commercial program across Europe, Southeast Asia, and the Middle East, signing distribution agreements in over two dozen countries.
FDA Submission for Next-Generation Device
Beyond Air submitted a PMA supplement for LungFit PH II, a smaller, lighter, and more transportable version of the current FDA-approved system.
Notable Partnerships and Recognition
Beyond Air partnered with Vanderbilt University Medical Center as the first luminary site for LungFit PH and announced the appointment of Bob Goodman to its Board of Directors.
Negative Updates
Net Loss and Gross Profit Challenges
Net loss attributed to common stockholders was $46.6 million for the fiscal year, with a gross profit loss of $1.7 million. Cost of revenue exceeded revenue due to depreciation and upgrade costs.
Operational and Market Challenges
Cost of revenue of $5.4 million exceeded revenue, driven by the depreciation of LungFit devices and onetime upgrade costs. Additionally, geopolitical factors and regulatory processes pose challenges in international markets.
Company Guidance
During the Beyond Air financial results call for the fiscal year ended March 31, 2025, the company reported a 220% increase in revenue to $3.7 million compared to the previous year, driven primarily by U.S. sales. They forecast at least $1.7 million in revenue for the quarter ending June 30, 2025, which represents over a 45% sequential growth and more than 145% year-over-year growth. For the fiscal year ending March 31, 2026, Beyond Air provided revenue guidance of $12 million to $16 million. The company also announced the submission of a PMA supplement to the FDA for their next-generation LungFit PH II device, which is designed for air and ground transportation. Internationally, Beyond Air has signed distribution agreements in over two dozen countries and has begun shipping LungFit PH units outside the U.S. The company reported a net loss of $46.6 million for fiscal 2025, with a cash burn reduction of over 28% from the previous year.Beyond Air Financial Statement Overview
Summary
Beyond Air is facing significant financial challenges with persistent losses, negative cash flows, and a high debt-to-equity ratio. Despite some revenue growth, the company struggles with profitability and relies heavily on debt financing, indicating potential financial risks.Income Statement
Beyond Air shows a challenging financial performance with consistent net losses over the years. The gross profit margin and net profit margin are negative, indicating the company is not covering its costs with its revenue. Revenue growth is volatile, with significant increases in 2024 and 2025, yet it remains insufficient to offset operating losses. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.30
Negative
Balance Sheet
The company has a high debt-to-equity ratio, indicating a reliance on debt financing, which could pose risks if revenue growth does not improve. The equity ratio is weakening, and return on equity is negative due to sustained net losses, reflecting poor returns for shareholders. The balance sheet reveals decreasing stockholders' equity and a decline in cash reserves, suggesting financial strain.40
Negative
Cash Flow
Operating cash flow is consistently negative, reflecting cash outflows from operations. Free cash flow is also negative, though there is a slight improvement from 2024 to 2025. The operating cash flow to net income ratio remains unfavorable, and the free cash flow to net income ratio indicates the company's ongoing struggle to generate cash from its operations.35
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.71M | 1.16M | 0.00 | 0.00 | 873.00K |
| Gross Profit | -1.66M | -1.31M | -555.00K | -588.00K | 873.00K |
| EBITDA | -41.89M | -59.03M | -58.20M | -42.70M | -22.02M |
| Net Income | -46.63M | -60.24M | -55.82M | -43.18M | -22.88M |
Balance Sheet | |||||
| Total Assets | 30.06M | 56.96M | 68.75M | 99.20M | 40.52M |
| Cash, Cash Equivalents and Short-Term Investments | 6.92M | 34.47M | 45.88M | 80.24M | 34.63M |
| Total Debt | 11.69M | 17.84M | 3.59M | 3.49M | 6.93M |
| Total Liabilities | 15.72M | 29.77M | 26.72M | 20.99M | 10.06M |
| Stockholders Equity | 13.58M | 25.05M | 37.91M | 72.70M | 30.46M |
Cash Flow | |||||
| Free Cash Flow | -44.10M | -61.76M | -36.89M | -24.58M | -20.53M |
| Operating Cash Flow | -38.22M | -56.01M | -33.01M | -23.13M | -19.64M |
| Investing Cash Flow | 14.90M | -12.23M | -20.59M | -1.45M | -890.00K |
| Financing Cash Flow | 16.65M | 43.17M | 2.70M | 79.45M | 30.33M |
Beyond Air Technical Analysis
Positive
0.21
Price Trends
0.19
Positive
0.23
Negative
0.33
Negative
Market Momentum
>-0.01
Negative
55.68
Neutral
88.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XAIR, the sentiment is Positive. The current price of 0.21 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.19, and below the 200-day MA of 0.33, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.68 is Neutral, neither overbought nor oversold. The STOCH value of 88.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XAIR.
Beyond Air Risk Analysis
Beyond Air disclosed 73 risk factors in its most recent earnings report. Beyond Air reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beyond Air Peers Comparison
Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $98.37M | 12.66 | 5.00% | ― | 0.29% | -22.13% | |
66 Neutral | $75.81M | 41.77 | 3.46% | ― | 24.75% | -61.29% | |
64 Neutral | ¥338.86B | 10.95 | -2.99% | 2.58% | 11.77% | -10.17% | |
55 Neutral | $195.20M | ― | -14.10% | ― | 5.73% | 72.50% | |
46 Neutral | $109.90M | ― | -60.68% | ― | 19.84% | 5.77% | |
45 Neutral | $333.48M | ― | -30.11% | ― | 15.32% | 15.73% | |
43 Neutral | $19.30M | ― | -241.40% | ― | 219.67% | 56.69% |
* Healthcare Sector Average
Performance Comparison
XAIR
Beyond Air
0.20
-0.40
-66.67%
FONR
Fonar
15.46
-0.89
-5.44%
INGN
Inogen
7.31
-1.69
-18.78%
SRTS
Sensus Healthcare
4.59
-1.10
-19.33%
NNOX
Nano-X Imaging
5.18
-3.32
-39.06%
LUNG
Pulmonx
2.73
-4.50
-62.24%
Beyond Air Corporate Events
Shareholder MeetingsStock Split
Beyond Air Approves Reverse Stock Split Proposal
Neutral
Jun 25, 2025
On June 20, 2025, Beyond Air, Inc. held a special meeting of stockholders where a reverse stock split proposal was approved. The proposal grants the board of directors the authority to implement a reverse stock split at a ratio between 1-for-10 and 1-for-50 within a year, potentially impacting the company’s stock structure and market perception.
The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Executive/Board ChangesBusiness Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Beyond Air Appoints Robert Goodman to Board
Positive
Jun 18, 2025
On June 16, 2025, Beyond Air appointed Robert Goodman to its Board of Directors, bringing his extensive experience in healthcare leadership to the company. Additionally, Beyond Air announced the submission of a premarket approval supplement to the FDA for its second-generation LungFit PH device, which could significantly enhance its market potential. The company reported a 220% increase in annual revenue for the fiscal year ending March 31, 2025, driven by the demand for LungFit PH and international expansion. Despite a net loss, Beyond Air’s strategic moves, including new distribution partnerships and regulatory approvals, position it for a pivotal year ahead.
The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.